Cannabis Science

Pe109 Cannabis for Dementia, Brain Health & Older Adults

The Science of Cannabis is evolving quickly, and new discoveries are showing its use as a neuroprotectant in preventing and possibly reversing Dementia in Older Adults. It seems like the group of people that can be helped the most by cannabis also have the most stigma they must overcome. Our guest is Linda Jacobson, Founder of Elders Together and we discuss how cannabis is one of the keys that may allow us to live a quality life past the age of 120.

Resources from episode, Project CBD & Americans for Safe Access


Episode Transcription:

Wayne Schwind, Host: Joining us today is Linda Jacobson. Really excited to have you on today Linda, we'll get a little bit about your background and your focus. But I'm really excited because this is - the conversation we're going to have is definitely a new territory that I don't - we've kind of hit on here and there but we haven't really went deep into and that's really focusing around cannabis, older adults, elderly and you know, cannabis being so new and the science and what products work for what and don't. You've had a strong focus on this, especially with your background, I think your experience really merges nicely into cannabis. So really excited for this conversation and appreciate you coming on.

Linda Jacobson, Guest: Thanks, Wayne. I am so excited myself. Your guests, and you, have taught me so much over the past year, year and a half and I'm honored to give a little bit back.

Wayne: Yeah, I appreciate it. I think I do most of the learning. So let's give listeners a little bit of you know, Introduction to yourself. When someone asks, "What do you do?", what do you normally tell them?

Linda: I normally tell people about my interest in helping people understand and adopt new technologies. So I've worked for my entire career as a journalist and teacher and marketer in the science and tech space, specifically in in science and technology related to health care and education. And about 10 or 12 years ago, I focused more sharply on science and technology for supporting brain health and lifelong cognitive fitness and finding ways to help people stay thinking clearly and ways for those who have cognitive impairment to enjoy life more. So about, oh about nine or 10 years ago, I started exploring the research found - findings around the benefits of cannabis for maintaining brain health and addressing symptoms associated with brain conditions. And I was fascinated and excited and I decided to add cannabis science and technology to my list of topics. And so I go out and I give talks to older adults about topics related to emerging science and new technologies.

Wayne: Yeah, that's so interesting. When you were focusing on - even when it was just science and technology Were you always focused on older adults and around brain health?

Linda: Only in the past 10 years or so I - in my early days, I was focusing on specifically on the technology of virtual reality and later augmented reality to use for healthcare and medical training and education and anatomical visualization. So I was working with lots of different types of, of scientists and then medical professionals to help them understand how they could use virtual reality in their - in their medical practice or their healthcare practice. But about 10 or 12 years ago, I actually had to become a caregiver myself. For my grandmother, who developed dementia. I don't think it was Alzheimer's. I think it was a different type of dementia, but I was - I was really disappointed by the lack of sophisticated or even basic technology as a way to help improve a person's life who has, who has a brain condition. So I, that's when I decided that I wanted to spend the rest of my career in helping develop virtual reality and augmented reality applications to help in elder care. And so that's, that's been my focus. And it was along this path that I came across the benefits of cannabis in this context as well. So yeah, so my focus really is on brain health and even even for people in their 20s 30s and 40s. You know, it's a it's a, it's just as we're discovering so much about cannabis right now, neuroscientists are discovering all new things about the brain. So I like to link the two.

Wayne: Yeah, no, it's amazing because it seemed like cannabis - you talked about earlier 20s and 30s. And then older adults - does cannabis seem to have preventative possibility and then once the - maybe if we're talking about dementia specifically or any other ailments that set in, cannabis also has kind of a therapy reactive treatability to it as well?

Linda: Yes, that's correct. So there is this theory, that is now going to be proven out in major research trials, that the proper use of cannabis can protect brain cells and even encourage the regeneration of brain cells, which is kind of mind blowing in itself. But then, by the same token, it's understood, documented, and there's scientific evidence that the use of cannabis is really helpful in reducing symptoms of dementia that cannot be treated any other way. There's, there's been no new dementia treatments in 15 years, the ones that exist, don't have lasting effects and also have really nasty side effects. So when we talk about dementia, we're just talking about this range of cognitive impairment conditions that could be mild and what we know you know, long time is people being senile or forgetful, all the way up to the, the dreadful loss of one's ability to recall, ou know things about their own life. (Yeah. memory.) So yeah, so the - when I first was discovering the, the evidence around the medical benefits of cannabis, the way I did it actually was kind of geeky I, I wrote patent applications for computer scientists and virtual reality inventors. So when you write a - start to set out to find out whether an idea is unique and has not been claimed by somebody else, you could go on to the US government website, maintained by the Patent and Trademark Office, and you could plug in search terms and and find what's been filed before. So out of curiosity about 10-12 years ago, I went on to the US Patent and Trademark Office website and I ran a search on the term cannabis and maybe on marijuana. And I was - I was shocked to find something that many your - many of your listeners may already know that the US government had filed and received a very broad patent for the use of cannabis medicine as a neuroprotective agent and a treatment for people with neurodegenerative disorders. And so there it is, right in black and white, the US government's own data about the benefits of cannabis for for brain health.

Wayne: Yeah, how does that - I mean, it's still Schedule I and they filed the patent. Is that just a huge hypocrisy that, I mean, no one's supposed to talk about? Because I mean, that completely contradicts Schedule I, right?

Linda: Right? Yes. I, you know, I it's, it was a patent that probably was filed with the anticipation or the expectation that at some point in the near future, it would be rescheduled or descheduled. And at that point, then the US government would be able to license this invention. However, it's taken so long that the that that particular patent is now expired, and -

Wayne: Does that open source it then?

Linda: Yes, in a way. Yes, yes. But there's even better, better science and better patents that have been done. So for all your listeners who may be curious I, I encourage doing a patent search for cannabis inventions and you'll see what's out there.

Wayne: Wow. So yeah, that was what you kind of did talk about dementia a little more there, and I want hit on that just deeper to kind of explain that to listeners. So that is really kind of a blanket cover all for any kind of mental or mind disability that starts happening could be slow, it could be extreme and Alzheimer's fits into that as a category a dementia. Is that correct?

Linda: That's correct. Dementia is kind of a catch-all phrase for a range of little-understood conditions or diseases or disorders in which parts of the brain are no longer functioning normally. And Alzheimer's disease is a type of dementia disorder. It is the most common and it's also very little understood. Neuroscientists are starting to think it's actually not one disease but a number of different conditions that have come together. But in the, in the area of dementia disorders. It's such an old school word "demented", you know, I remember as a kid listening to the Dr. Demento and dementia was such a such a Dickensian term, but there are dementia disorders with other names such as vascular dementia, and Fronto-temporal dementia. And the list goes on. And with each of them having different types of symptoms and different potential causes, but none of them has a treatment. None of them is understood well enough to prevent it or to cure it.

Wayne: Yeah. So it's really unknown. And it sounds like - is cannabis leading, I mean, the one of the best discoveries we found that has any kind of preventative or treatment that we've discovered for this, then it sounds? Like (it seems like it) right it's kind of early for understanding it right now.

Linda: That's right. That's right. Well, people are starting to understand that the endocannabinoid system plays a large role, a potentially large role in the processes associated with aging. And it's it's possible, theoretically possible that deficiencies in the endocannabinoid system lead to decline in brain function. And so it's theoretically possible that supplementing the endocannabinoid system with external cannabinoids and terpenes and the other wonderful compounds in the plant could actually prevent the progression of decline, or least mitigate the symptoms associated with the decline. I'll give you one example it is well documented that people who have serious dementia, whether they're living at home with their loved ones or already in some type of facility, they almost all experience this sudden feeling of agitation and anxiety and fear right around the time when the sun starts to set, no matter what time of year it is it whether you know it's summertime and it's late in the day or winter and the sunsets early or you're in this hemisphere or across the world. It's universally experienced so much that this symptom has a name called "Sundowning". And cannabis is widely used in Dementia Care around the world to reduce sundowning. And it's effective and it's it's, it changes lives. It's changed lives, for caregivers and for families and definitely the people who have this condition

Wayne: Wow. Is that sundowning something to do with the endocannabinoid system changing during some the sun setting?

Linda: Well, that we don't know. That, that will be, I hope, probed in the upcoming studies being funded at neuroscience centers of excellence like Harvard and MIT and in the - in the UK, in the United Kingdom there the Alzheimer's research organization just funded major research study to try to identify the answer to your question. With a great influx of funding, it's also happening in Australia these studies to find the answer, and probably the world leader in exploring the use of cannabis to mitigate cognitive disorders is, is Israel.

Wayne: Fascinating. I've got so many questions, I'm trying to see where we should focus. I do want to make this episode, you know, we have a lot of people that are in the industry that listen but I want this to be consumer facing as well. And so let's talk a little bit more about the endocannabinoid system. I think a lot of people in the industry know about it, but if they're a consumer or an older adult outside, maybe not. Can you explain what that is? Exactly. And something fascinating. What I've heard from a lot of doctors in school is they teach about it for about a week or two at most. And it seems to be one of our biggest nervous systems in the body, which seems hugely important, but taught very little in school. Is that accurate? And if so, why? And what is the endocannabinoid system as well?

Linda: Right? Yes. So it's so accurate, it it's a it's fascinating to start learning about the politics around education, medical education, but setting that aside, and without, I don't want to miss, misrepresent the people who discovered this and because it happened in several places at once, but let me just explain very briefly that the human endocannabinoid system - Endocannabinoid is actually short for endogenous cannabinoid system, that means something inside you. So the human endocannabinoid system is really part of a whole new body system that works in conjunction with the other body systems. And those include the central nervous system, the muscular skeletal system, the gastrointestinal system. So the human endocannabinoid system is known to basically help manage processes in the body that that we rely on day to day - from movement, to sleep, to common conversation, to running, running with your dog on the beach, you know. So the this, this human endocannabinoid system generates its own neurotransmitters that communicate with parts of your body to make sure your body works correctly, but it also responds to the compounds in the cannabis plant, right? So, so cannabis is is known for its cannabinoids, which are known scientifically as phytocannabinoids or plant cannabinoids. So, the cannabis plant compounds interact with the human cannabinoid system to produce desirable results which is basically the functioning of your body. And and it is now believed that the human endocannabinoid system plays a fundamental role in, in protecting the body from disease and also in helping to keep the rest of your body healthy while there is some disease happening in the body. So it - there's some fantastic resources I, I hope I didn't do it just some injustice with a really high level explanation but the the fact is that the scientists are discovering and now starting to really study the, the mechanism known as the human endocannabinoid system and slowly but surely it's being adopted by - very, very slowly - being adopted as a topic for for teaching and study in medical schools in the US.

Wayne: And we don't have to jump into the specifics, but is it quite simply the prohibition and propaganda of not wanting to, you know, recognize this natural relationship from this cannabis plant with the system in our bodies and government, you know, trickling down to education and universities not wanting to discuss it and learn it? Is it that just simply because of prohibition? Or is there, more?

Linda: I would say that that is definitely a factor because of the legal, the legal restrictions on the research that could have been going on for many years to identify it. But also, it's, you know, to just set aside blame, or pointing fingers for a minute, the - it's also the advent of very sophisticated medical imaging systems that have enabled this discovery. So the, there's like these nuclear, you know, magnetic resonance spectrometry systems that are required to explore the body at this molecular level, have only really been developed and implemented in the past couple of decades anyway. So it's partially politics and restrictions, but it's also just the progression of scientific discovery.

Wayne: Hmm, got it. Yeah, I learned about the endocannabinoid system a couple -a couple years ago, probably only and I was just fascinated to learn that our own body produces cannabinoids internally, and then when we're off balance or they're low levels, and we're not balanced for whatever reason that might be even stress, anxiety or sickness, and then this plant is literally just filling the void that our own body should be creating that it's not, and it's like they're that close, they're that similar? It's like, it's too eerie, how much, that natural that you know cannabis is to health and well being , that is just it's crazy to think of all this prohibition that we're just pushing through finally now.

Linda: Right? Yeah, it's amazing. Well, you know, the recent research has identified inflammation. And I'm not talking about in this case like a cut or a burn on your skin but inflammation the brain like it - in the blood vessels and in tissue in the brain, well, that that inflammation is possibly a culprit in the development of depression and neurodegenerative disease and other conditions that tend to develop later in life, right? So we know that inflammation is bad and oxidation is bad. And, and it's believed that depression this inflammation may actually lead to the development of dementia disorders or at least cognitive impairment. And so that - it's also clear that cannabis compounds are anti-inflammatory, really effective at reducing inflammation. So now, now it's really starting to be understood that in low doses, cannabis can reduce inflammation and improve mood and reduce stress in the proper doses. And and so there's this - There's a, you know US scientists research scientists now saying that if if we could use compounds derived from cannabis to restore normal Endocannabinoid function, we could be reducing inflammation and potentially helping to stabilize moods and, and reduce depression and anxiety. All of which, you know, it's well understood that stress, depression and anxiety have a relationship with the development of dementia.

Wayne: Yeah. Do you think cannabis will be covered one day by health insurance?

Linda: Yeah, you know, I do. I yes, I do believe that there will be. I do believe that at some point, these alternative approaches to medications will be covered by health insurance. The fact is that the dementia disorders do not have, like diseases symptoms that require medical care, but do create dependency so that people who have dementia need help with activities of daily living like getting dressed or brushing their teeth or taking a shower or preparing a meal. And, and until recently, families had to pay out of pocket for professional help for anybody who needed this kind of assistance. And we've just now just now the whole US Medicare system is is going through a change to allow reimbursement for professional care that's non medical. So there's changes going on at, at the administrative - at the federal level to allow reimbursement for care because it keeps people out of hospitals and avoids people sapping the larger institutional healthcare system, and I believe cannabis, cannabis treatments will head in that direction, too.

Wayne: Yeah. Yeah, I want to we were talking a little bit before we started, I want to make a distinction for the listeners, and then go a little deeper into some specific questions around, you know, what products what questions to ask. The distinction is we've been talking quite a bit about dementia and elderly patients. But you also have a focus on what you'd call older adults and even sports performance and more kind of the well-being, what maybe you would call recreational, maybe not, but do you want to make the distinction between those two categories, older adults versus elderly? And then I've got some questions to ask around that, how cannabis works for each group, similarities, differences, things like that.

Linda: It's a really interesting topic you know, the semantics of aging (Yeah) are like a practically political now you know, and the aging movement doesn't have any single one, kind of, you know, Rosa Parks or Martin Luther King Jr. or Gloria Steinem or Harvey Milk, but I think that, that that person will emerge. And there are definitely ways that we talk about older people that are really alienating and so, so I don't use the term seniors, but I will use the term older adults to refer to say people over 50. And then we're talking about decades, right? People are living routinely now into their 90s and their hundreds. So a person who's, you know, 92 may be out there running, running marathons and sprints and playing a mean game of tennis while a person who's 72 may have advanced dementia, and not be able to live alone anymore. So you can't even distinguish people anymore chronologically, that way. So the the ways in which we take care of our brains when we're middle aged, 40s and 50s, are really going to have an impact on our successful aging as we get into the 70s, 80s, and 90s. So, it's, you know, there's a continuum there of awareness and self care. I have to backtrack, and I apologize but, regarding that discussion about insurance coverage of cannabis medications. I just want to say that that actually is already happening because there are FDA approved pharmaceutical medications that are covered by insurance it with a proper prescription and Sativex is one you know that there is a isolated synthesize THC product that's used In, in dementia care routinely, that's produced by GW Pharmaceuticals, and that's a regular FDA, you know, sold by pharmacies. And just recently, the FDA approved an epilepsy medication called Epidiolex, which is a whole plant CBD extract, to treat severe epilepsy conditions. So those are covered by insurance and that is another signifier of the coming change. But yeah, just so those may be given to people who are have early onset dementia when they're in their, in their 60s or 70s. Or a person who is 110 now, but yeah, so go to the more recent question, Wayne, and I'm going down different branches road, back main, the main trunk of the question, which is - Yeah, I, I'm a baby boomer, I was born near the end of the baby boom, I don't normally group people together by the generation in which they're born, I group people according to their, you know, their, their independence and the health condition and, and the way they engage with the rest of the world.

Wayne: Yeah, that's a really good point. And I like that. And I think that's a trap sometimes thinking, well, this age bracket versus this one, but like you said, someone could be pushing 100 and be the athlete and someone could be early 70s, 60s and, you know, have the issues. So that's a really important point I think to make when we talk about cannabis. And so with that in mind, you know, there's so many different kinds of cannabis products out there. And the science of it. You know, in this industry, we learn a lot about the different compounds and the interactions and how they mix together or using different ones with other ones but for a consumer, it can be very complex, I think and confusing. Our product selections different for what we might call elderly or someone that is dependent versus older adults who are independent and maybe looking for more of that well-being or, you know, in performance enhancement, you might call it (Very different.) How was that?

Linda: Well, you know, it's really great that people know about the effects of the plant compounds and the different formulations and how they work. But it's also really important to know that as we get older, the less THC is required to achieve the minimum desired effect. And not only does your chronological age affect your reaction to a cannabis product, so does your genetic background. You know, what, what, whether you're descended from Eastern Europeans versus Africans versus Asians, that will affect your reaction to THC. And so will your medical history, as well as the, the medications and supplements, if any that you're currently taking. So it's really important to be patient. If you haven't found the right combination of compounds to achieve what you need, you know it everybody, everybody's different and the older we get, the more different we get. You know, there's this truism that when you've seen one, when you've seen 1 85 year old, you've seen 1 85 year old. You can't, you can't generalize the the health condition or the way and a single 80 - all 85 year olds will respond to the same product.

Wayne: Yeah, yeah, that's what makes cannabis difficult as there's many different compounds and it's, I guess even in pharmaceuticals there's a little bit of trial and error to see if a product works. With cannabis products when you're talking to people do you - Is it still a lot of trial and error and experimentation to figure out what works, or how do you go about recommending either a specific product or how they should find a product that might work for them?

Linda: That's the most common question asked when I talked to audiences with, for community groups or I go into an assisted living community or I talk to a group of professional caregivers and, and it's, it's a little frustrating right now that there is no one single answer and that you I do recommend the classic you know, start low and go slow, but it's important to find out the goal of taking the cannabis medication so. So that's like the first thing you start out with is to prioritize the, the desired outcome, because you might be willing to experience being high if it'll help you get to sleep better. You know, you might say, Okay, I don't mind being a little dizzy if the trade off is that I get to sleep through the night, or someone else say, you know, I don't want to be dizzy. I don't care if it makes me sleep or not. So, you know, the, the goal, the top symptom to address is really where you go first in trying to identify the product. And then you have to talk with folks about what their budget is, and what how they want to use the cannabis. You know, some people are really wary of smoking. Others are not. So I mean, one of the most common questions is how do tinctures work? So there's a real interest in understanding these new formulations and ,and how they work. It's a lot of fun that - you know that you talked to older adults and it's really easy to get a good laugh because there's so many is, you know, so many decades of nonsense that we have to, no pun intended, weed through, you know? So I think it's really important to know, either as a consumer or as a professional helping a consumer that most older adults about, you know, people, let's say 50 and older, have a very different relationship with cannabis than anyone born after 1970 due to just the decades of propaganda, demonization of weed and incarceration, so that, that's - that factors in to ability to like have an open mind and an open heart about, about using this. So you kind of have to peel back these layers of the onion to get to the heart of the matter which is - what do you want to do? How much money do you want to spend? What - do you want to get high, or is that a fear that you have? And - and, you know what? What is it? What kind of method do you want to use? What - What is your preferred method?

Wayne: Do you find a lot of older adults almost have guilt or shame even wanting to try cannabis still with that like momentum of that propaganda?

Linda: Absolutely. Yes. 100% there's still a lot of internalized stigma around it and I, I, I go in and talk to audiences of residents at assisted living communities. And they'll be very eager but they, then when I say well, would you like to find out how you can try some and go get some, though they'll like, look around. They'll say, well yes, but only if you don't tell the manager. You don't - Oh, yes, but don't ever tell my daughter, or Yes, but I can't talk to my doctor about it. So this is, this is prevalent, this is pervasive. And I'm in the - I'm in the Bay Area, I'm in Northern California, where you know, hippies have been out on Hippie Hill and Golden Gate Park smoking joints for 50 years. And even here, there's this strong, strong stigma associated with cannabis use. And with the people, and with the people who use cannabis and I think that may be keeping, keeping older adults out of dispensaries too you know, they can't relate. So yeah, it's it's, it's a big problem, and it's one of my goals is to reduce the stigma, and help normalize the topic just to talk about it. And not feel like you're going to be judged.

Wayne: Yeah. Do you see it shifting? Do you notice a change?

Linda: In different regions, I notice a change. So, there's conservative neighborhoods and cities where the - it's a little bit more slowly changing. And then there's the more, you know, progressive or liberal or, you know, more diverse areas where people are just annoyed that their city has a moratorium on dispensaries. So yeah, it's not - it's not consistent. I think it's generational for sure, but regionally people differ in the way they embrace it. (Yeah.) Or whether they compress their lips and hold their arms like your mom when she was angry, you know, you're, I get all the time, you know.

Wayne: With cannabis consumption and you know, fitting into a lifestyle and how you see this evolving into people's well-being and we can separate it for each group, older adults versus elderly, elderly that might be dealing with more of a medical ailment. Do you see cannabis being consumed daily for older adults? Or would it be kind of spaced out or multiple times per day in lower doses? Do you see it becoming like a regular part of a healthy lifestyle living once you're in an older age?

Linda: Yes, yes. And I - and I have heard and seen medical doctors with geriatrics expertise who practice cannabis medicine just explicitly saying it doesn't work if you use it once. And its most effective in small consistently spaced apart administered doses. So, so much like a good diet, like you don't only eat, you know, once a week, (Yeah, right.) So yes, I do see the emergence of a dosing schedule that is based on very low doses administered throughout the day. Similar to how just, how a painkiller might be, you know, you a wrench a muscle, you know, the doctor will say, Okay, here's some, you know codeine with Advil in it, and take it either four times a day with water or, or as needed. So a lot of the current medical doctors who have recommended cannabis for elderly people who are in the care of others will write on the recommendation the acronym PRN. That stands for Latin term meaning take as needed. So yeah, there's also that approach too, where if you have a sudden spasm of pain, you might grab a tincture right away or a vape pen. Whereas if you're trying to encourage you know, 12 hours of calm you might use a very heavy duty patch instead.

Wayne: Is that a big benefit, and unique, around cannabis that you can almost take it on demand as you need it and how you notice your body's reacting versus it seems like many pharmaceuticals are, you know, every six hours one pill and very regimented and you're not supposed to go higher or lower with that - does cannabis have a lot more I guess margin for error would you call it or flexibility in its use?

Linda: In my opinion and my, my experience it does because - just simply because there's no one cannabis medication and you know what, you might have a CBD rich tincture or, or vape or something that you use throughout the day to minimize anxiety but then you may only go for your high THC formulation at at night for, for going to sleep or for reducing exercise pain. But then it really depends on the, on the situation in which it's used. And a lot of medical doctors and other clinicians really want those dosing regimens identified and, and approved and articulated and, and I - and that's where a lot of the research is going is to coming up with those dosing regimens because a lot of doctors won't talk about it because they don't know how to guide their patients on how to use it. So there's not only this fear of losing their license to prescribe opioids, which is I think an unfounded fear but a fear nonetheless. But there's also this general lack of knowledge that they were taught in medical school about how to prescribe pharmaceuticals based on the you know, pharmaceutical, the pharmaceutical companies insights and discovery from their staff scientists and how to use it and achieve the right effect. And that that's lacking right now in cannabis meds but it's it's emerging. Some amazing medical people talking about dosing and consistent titration approaches, such as Ethan Russo is a great one and on the east coast and here in the West Coast, a doctor named Hergenrather, Jeffrey Hergenrather, those are just two right off the bat who are talking about specific dosing regimens and, and frequency of administration.

Wayne: Got it. I saw on your website to you do some training and consulting with family care, or for family care providers. What does the landscape look like with family care providers? I'm guessing this is very regional across the country, but you know where it's not still not legal for cannabis but Are they starting to adopt it recommend it to their patients? How does that part of the - not industry but medical care sector - look?

Linda: So for many people - and let's let's focus right now on the the brain fitness and and helping people to get through the day if they have cognitive impairment. There's no effective pharmaceutical or surgical treatments and doctors don't know what to do. And so there's a lot of openness and almost desperation on the part of family caregivers to find something that will help bring relief to their loved one. So people in - I'm finding that family caregivers versus let's say volunteer unpaid caregivers are incredibly open, but a little - A little frightened by what they think they know. Such as the possibility of causing psychosis or making grandma high and and giggly and even watching you know, Dazed and Confused right, there. There's a lot of fallacy a lot of fear of getting high. But the the professional caregivers, more and more are having an open mind because the institutions associated with their profession are starting to issue statements saying, guess what, folks, this is really valid and we need to be looking at it and we need to lobby for legalization so we could do research. So this, this is the - for instance, the American Nurses Association is very specific in their guidelines for nursing with cannabis. The, the American Physicians association is another one, that's very, very vocal in talking with, with people about the need to understand and research cannabis, so it could be used, you know, with greater precision and greater evidence. So, so there's, you know, these these different bodies, even the American Medical Association, which has a lot of ties to the pharmaceutical industry, is starting to relax its stance, but I think that that's, you know, it's going to come down from these, these august bodies, you know, to influence the medical people and influence the faculties at medical schools and across the board and into the, you know, the legitimacy of this as a strategy for promoting and maintaining brain health.

Wayne: Yeah. What would you recommend, I think if, you know, for older adults, where do they go? What steps can they take if they have that stigma they, they're worried about talking to their family care provider - and maybe even if they're okay with it, but they might not know that, you know, they're in a state that's legalized, they can walk into a dispensary, but that I can imagine is, if you have that stigma is even heavier to walk into one of those stores. What steps can they take? Like how do they gradually or carefully approach cannabis and see if it can help them?

Linda: Yeah, I, I always recommend two websites for their incredible online free resources that are, that are written for, for these audiences. And, and I'm sure you've you've heard of both and you may have bookmarked them, like I have on every single device I have. One of them is Project CBD. So the website projectcbd.org is just a cornucopia of cannabis education that addresses specific conditions associated with aging. So you could download booklets and articles. They, project CBD even publishes a list of, of interactions with other, with other drugs that are - that I routinely hand out to professional clinicians and caregivers. So you could download a booklet called a Primer on Cannabinoid-Drug Interactions by Adrian Devitt-Lee, and that's a Project CBD publication. So that is something that any, any cannabis aficionado should be able to pull out if they're asked, okay, what happen- My mom is taking a blood thinner, what do I need to know? So that's one great site and another great resource is the organization Americans for Safe Access and their website safeaccessnow.org also provide downloads of free booklets about the use of cannabis for specific groups of people and specific disorders. So you could, you could download a whole booklet on cannabis and aging that will provide this terrific overview of, of ways in which cannabis could help somebody who's dealing with some of the health issues associated with, with aging. And that, that, like the - one of the most common ones is insomnia, for instance, and just to demystify when I talk about these mysterious, old people afflictions, they're pretty much things that all of us experience all through our life, but that seem to get worse as we get older. (Yeah) so yeah, so those - I send people to safeaccessnow.org and to ProjectCBD.org and also on YouTube. There are videos by geriatrics clinicians in which they speak specifically about cannabis for older adults and they give great advice to consumers. So, Eloise Theisen, T-H-E-I-S-E-N, is a great name to look up on on YouTube to find her lectures. Dr. Lori Vollen, V (as in Victor) O-L-L-E-N also has some great tutorials on YouTube and then you could find her website so and, and the list goes on. So that and that's the resource that I like to provide to people to kind of be a conduit to this information.

Wayne: Yeah, we'll put links to those in the show notes as well so people can go to those. How - so I'd like to look at you know, THC products. If I someone listening is in a state where cannabis is legalized either medically or recreationally versus CBD products that can be bought online if they're not in a state where they can go into a store. So they they find these resources, they dive in, they learn whether it's them, or maybe their caregiver if they you know have a medical ailment. They're like, all right, this type of product, they're finding something that works. If they're not in a state where they can walk into a store, how do you recommend going through the process of trying to buy something online? Which is really risky right now because it's, you know, a lot of companies that are trying to make a quick buck. Some great companies out there, how do you kind of talk someone through that?

Linda: Yeah, you know, I've heard the great phrase, I went to the Cannabis Nurses Network conference earlier this year, and someone described CBD as the gateway drug to THC. And, and I - you know, you could always start with exploring CBD, there are unbiased review sites that will recommend highly-regarded CBD products for treating certain symptoms, so I - you know that that's always a place to start could be in exploring whether some full spectrum hemp based CBD product can provide some relief to you while recognizing and, and basically you know taking as fact that the - that you're missing the entourage effect right of the whole plant with THC. But that's, that's where it - that's the only place to start. There's really no other choice unless you could travel to a legal state and then experiment and not all legal states will, will allow out of state residents to come to their dispensary. There's, there's a few - there's a few states that do accept out, that do allow out of state adults to, to buy from their dispensaries and use their products while they're in the - while they're still in the same state. So yeah that, that's - right now it's the it's the only option when in those states where you can't access CBD - I'm sorry THC. So, yeah.

Wayne: Let's talk about some of the - I saw on your website as well. You said "marketing hype" that you hear in cannabis, and there's - it's almost like a new language, these different words we're using to describe products. So I'd like to talk about a couple of them for consumers as they're looking for products and they might be able to understand what these words mean versus what they don't. So starting off you mentioned there what you said full spectrum versus you know, and whole plant or hemp. Those are a couple that consumers are going to hear -, what does full spectrum or whole plant mean? And what does, maybe we call it, the isolated version - what's the differences there? Should a consumer be looking for that difference or care about that?

Linda: Yes. And, and right now I have to say that I learned so much of what I learned from your own episode 50 (Yeah, that's a good one) with Emma Chasen and, and all the great materials that you and she have put together and made available to the world. So, the - and the question that you just asked me is, I made a list of the Top 10 questions I hear the most from older adults. (Let's go through those, yeah) And, and I ranked that one at number three, you know, I you know, as number two and number three. What's the difference between hemp and cannabis and marijuana? And then three, what's the difference between THC and CBD? And so in talking about Full Spectrum and whole plant. Really, this most simplest way to convey that is to say either you're using all the compounds in the plant to create your treatment to extract and process and create your cannabis medication or you're pulling out some of the, some of the compounds and isolating them from the others. And there is a real belief that the combination of all the compounds in a plant that make an extract much more effective and that, a lot of studies are going in right now toward understanding - trying to understand and document and, and benchmark those, those advantages of using a compound or an product made from the cannabis plant that has trace THC in it, whether traces or not, or the so called hemp plant that has been traditionally cultivated for other uses and not getting high. So it's it's a really rich, deep, very nuanced topic and it's - sometimes it's hard to encapsulate the answer in just a few sentences but that's that's where I, I just focus on you know, using all the ingredients or taking out some of them.

Wayne: Yeah

Linda: Full, full plant - whole plant or full spectrum.

Wayne: Yeah, versus maybe just CBD only or just THC only from the plant. And that's, that's kind of where I wanted to go a little deeper because I was asking about buying products online. It seems like many of the CBD products that are available online are mostly made from isolates, which is CBD only, you're not getting full spectrum. Is there a way for a consumer to identify that when they're looking at a product or is it kind of a mixed bag of knowing what exactly you might be getting? I guess someone could tag it full spectrum. You hope they're telling the truth. But is there a way to identify a CBD isolate product?

Linda: You'd have to ask the manufacturer for the certificate of analysis. You know, that's that's really where the, you'd hope there they'll be transparent, honest information about the test results for that product. And, and if the product has not been tested by a third party lab and issued a certificate of analysis around the contents, then you don't want it. So So. Yeah, I there's very little regulation and, as you know, and there's also, from state to state, different laws about what you could say on the package, you know? So you know, you're not allowed to sell sparkling water that has CBD isolate in it but you, on the package but you are allowed to sell a sparkling water that has hemp extract, even though it's the same thing. So it's very confusing for consumers right now, and there's no easy answer, other than being able to confidently identify the source of the ingredients and the, you know the, the strength, the potency and the quality of the ingredients.

Wayne: Yeah, that is what I've seen on packaging - hemp oil or hemp extract - and I've wondered if that might not necessarily mean it even has CBD in it. (Right? Yes) If it's a, yeah, supplement product more so right? (Or made from hemp seeds right?) Yeah made from hemp seeds. Yeah, that one was always confusing. I also thought you know, we were talking about health insurance covering cannabis and those two products you mentioned Epidiolex and Sativex both being isolates. Is that correct? Not a full spectrum product?

Linda: Epidiolex is the first full spectrum product that's been approved through randomly controlled trials by the FDA.

Wayne: Oh so it is full spectrum? Okay, that's good.

Linda: And there you know, believe it or not, the FDA has a really robust website about their opinion of cannabis products. So there's, it's - you could find it really easy easily on the on the US Food and Drug Administration website. They have a really lengthy and quite well written section called "what you need to know and what we're working to find out about products containing cannabis or CBD." And, yeah, so it's, it's something that you'll put on your site.

Wayne: Yeah, we'll put it in the show notes too. I hadn't heard of that one. Yeah, I'm definitely gonna go dive into that on the FDA website. That's great. Well that's such a good I think overview and there's absolutely so much more to dive into for people that want to learn more and you know, kind of figure out how cannabis might work for them. I kind of wanted to end on if, and let me know if you don't want to dive into this but you know, your grandma getting dementia and kind of sparking your interest to look at cannabis and go into this area. Would you mind talking at all about her - was she using, did she try to use cannabis to help with that? What that experience was like, and maybe some, whether results or the experience that others might be able to learn from?

Linda: That, and you know that - that's such an interesting topic for looking back because I at the time, was using cannabis, I've used cannabis my entire adult life and now I know, in retrospect, I was using it medically. I was using it for help with anxiety and depression. But when my grandma had developed dementia, I was still not outspoken with my family or friends about using cannabis myself so it never would have been an option. But you know, what happens with people who have dementia disorders, when they're really advanced, is that they forget people around them and they can't make new memories and they don't remember recent history, but they go back to their childhood or their early adult years. And those memories can cause a lot of anguish or, or not, you know, depends on the person's life, but my grandmother was in a boarding care, you know, a small, private assisted living community and, because she couldn't live alone anymore, and they were is really no medications and the the, the worst her dementia got the less she remembered English. So my grandma was an immigrant who arrived in this country as a holocaust refugee and spoke German and Yiddish. And as her progression, as her dementia progressed, she started forgetting how to speak English and the caregivers did not, like thought she was like speaking gobbledygook and would give her sedatives, you know because they thought she was losing it.

Well, okay, fast forward to recent past and at Harvard, McLean psychiatric hospital recently, there was a patient who was an elderly gentleman named Mr. Spier, who was the head of a beautiful and very well funded, philanthropic family foundation, but he as a boy who had been imprisoned in the concentration camps. And he developed Alzheimer's in his 90s and was brought to the hospital for hospice care. And similar to my grandma's experience, he kind of regressed but became very, very fearful. He thought he was a kid back in the concentration camps and the only medication that helped him, that the family brought in even though the Harvard psychiatric team didn't know about it, was cannabis. And cannabis restored this man's calmness and his comfort. And after he died, the family decided to devote funds from, from his foundation to exploring how cannabis could help other people who were in that situation. And so this was just recently in the news that the, that the - Harvard has received a significant amount of funding from a family similar to my family, but with a lot more money, who could help people do really, really important research into cannabis to treat agitation and help sleep for people like this. So the Spier Family Foundation, you know is an organization that's S-P-I-E-R they're doing amazing work and I hope I wish - you know I get really sad when I think about how I wish I could have brought cannabis to my grandma, but I never thought of it.

Wayne: Yeah, that - I mean, that's the stigma that, the momentum of all that it's. Yeah, we're finally overcoming it, starting to, pass the tipping point hopefully. And it's just, it's crazy to think about the grief and suffering that could be prevented or at least alleviated significantly. So Many people, I can't imagine how we're going to look back in 50 years on this period of prohibition, it's going to be sad, but thankfully, we're making changes now.

Linda: That's right. That's right. You know, there's this this old like kind of silly saying that you can't teach an old dog new tricks. And now we know that scientifically, that's not true, that - you know that older people can learn and retain what they learn. So, you know, we're going to be teaching a lot of old dogs, a lot of really great new tricks and learning a lot along the way. So it's awesome that you spent the time talking about this for our elders and for our future selves.

Wayne: Yeah, I want to end on this question - with your focus on science and tech and bringing cannabis into this for brain health and longevity, I would say - do you expect the human life expectancy to you know go up in let's say, 50 years, 100, where we're living around 100 with quality life? And maybe dying - sounds crazy to say, but passing away around 120-130 being more normal? Do you expect that to happen with all this technology advancements?

Linda: Yes. Yes, the - the longevity research community really does believe that it's possible to extend lifespan by 50 years in the next couple of decades. And that it actually - it can be a lifespan where you're healthy and happy. You know, right now, we wouldn't want that. Right now dementia is happening because scientists figured out how to keep the machine going the meat, right, our organs that - they've got everything figured out to some extent except the brain. So that's why we have dementia because we're living longer. There's a greater life expectancy in developed countries. But we don't know how to keep the brain going to so it's it's a really interesting time. Yeah.

Wayne: That's amazing. Linda, thank you so much. Where can people find you if they want to learn more and any projects or anything you want to let listeners know about that you want to share?

Linda: Thanks for asking, Wayne. I have a website called elderstogether.com and I would welcome any questions or suggestions or outreach through my email there linda@elderstogether.com, and these days I am partnering with registered nurse Barbara Blazer and we have developed courses for assisted living staff people, assisted living managers, to help them understand the use of cannabis in dementia care and we received approval from the California Department of Social Services to present that course. So we're, we're scheduling that right now and actively engaging with care providers, both - both family caregivers as well as professional to help them be more effective and, and help people achieve a lot better quality of life.

Wayne: Amazing that's, that's so cool to hear the state approving that to be taught in these facilities and we've also talked about possibly having Barbara on in the future, so that could be a really cool conversation as well. And I'm fascinated by this. It's definitely a topic or area we haven't gotten deep into, so I'm so happy that we did, I think listeners are really going to enjoy this one. I think it can also help a lot of people, so thank you, Linda, so much for coming on.

Linda: Oh, thank you Wayne! To your long life and better living, and I look forward to hearing lots more from you about this and helping you get the word out.

Pe107 How you Consume Cannabis Matters

We’ve talked a lot about the science of cannabis and predicting effects, cannabinoids and terpenes matter, but how cannabis is consumed also greatly influences the effects you experience. Our guest is Collier Hansen, Marketing Lead at Ghost Vapes. We discuss the next frontier of vaporizer technology and science with marketing and branding insights for cannabis companies.

JOB OPPORTUNITY: Ghost Vapes is hiring in LA, discussed at end of episode.


Pe106 International Research on Cannabis

Research on the Science of Cannabis is expanding quickly. While new discoveries are being made faster than ever, how these new findings will be integrated into commercial cannabis products is a new frontier.

We discuss the past, present and future research & studies that will shape the future of cannabis with our guest Jahan Marcu, Director of Experimental Pharmacology and Behavioral Research at IRCCMH.org


Pe105 Educating Brand Reps & Budtenders is Critical

There are more Cannabis Brands than ever, making the job of Brand Rep increasingly difficult. Budtenders must not only stay informed on new brands, but also on a constantly evolving knowledge base of Cannabis Science.

Today’s guest talks education and training for both of those critical roles in the industry. Learn how Brand Reps can break through the noise getting into new dispensaries and how Budtenders can stay well informed while providing the best customer experience possible. We are joined by Bridget Gavin, Founder of Symbiosis Cannabis Education.

Pe102 Cannabis Science, Merchandising & Best in Class Budtenders

How do Dispensaries take the leading cannabis science and connect it to merchandising and sales? How can Budtenders communicate the science to consumers for the best experience possible? What strategies lead to repeat customers and word-of-mouth marketing? We answer those questions and more with our guest Andrea Sparr-Jaswa, Director of Education at Farma, a dispensary in Portland, Oregon.

JOB OPPORTUNITY: Farma [Careers] is always looking for compassionate and curious team members, discussed at end of episode.

Pe101 What’s next for Cannabis Science?

What do we really know about the Science of Cannabis and what don’t we know? Can we quantify the medical benefits of the plant? What new cannabis studies and research are on the horizon? We mix science and business in this episode with our guest, Ben Armstrong, Ph.D., Lab Director for Juniper Analytics.

JOB OPPORTUNITY: Juniper Analytics is hiring for a Lab Analyst, discussed at end of episode.

Pe100 Cannabis Business & Science Insights

Episode #100 :) Thank you for listening and supporting us along the way! We did something different for this episode. We pulled 20 clips from 20 different episodes that we thought provided great insights and value for the cannabis industry.

Please share, forward, text or email this one to a friend or colleague that should listen to the Periodic Effects podcast! Cheers to the next 100 :)

Pe098 Cannabis Design, Science & Entrepreneurship

This episode covers Cannabis Design, Science, Branding and Digital Marketing. We discuss the issues in researching cannabis science online, how design can be used to clarify your message and what digital marketing strategies can be used to find your ideal customer. Our guest is Charlie McElroy, Founder & Creative Officer of Goldleaf.

Pe095 The Science of Growing Organic Cannabis

Our guest, Jeff Lowenfels, has the longest running garden column in North America, having never missed a week in 41 years! Is white ash = quality a myth? Will autoflowering cannabis be the future for home growers and/ or commercial operations? What is the soil food web? Why should we care about organic growing practices? We discuss all those items and more!

Pe092 Science of Cannabis Series_12

Why do some people not feel the effects of edibles? What are the effects of THC when using cannabis across different consumption methods? How do terpenes affect your experience when consumed orally? And how can Budtenders communicate the Science of Cannabis to consumers? We answer these questions and more with Emma Chasen from Eminent Consulting.

Episode Transcription:

Wayne Schwind, Host: Joining us again is Emma Chasen, another science of cannabis episode. I think this is number 12 in the series, so thanks for joining us again today, Emma. I love having you on ready to learn something new.

Emma Chasen, Guest: Yes, thank you so much for having me Wayne, it is always such a pleasure.

Wayne: Yeah. Well, let's start off with you know, give the listeners well I'll do a little bit overview of what we're going to cover in the intro so listeners will kind of know what we're going to walk through. But let's start off with some of the points that you brought up. And I think today we're really going to focus on THC, maybe a little bit with terpenes, how it's consumed, and what science and what the conversion processes happen in the body and how that affects the high or the experience. So starting off you mentioned the hydroxylation and oxidation of THC through the consumption methods. Do you want to talk a little bit more about that and then I had a question on top of that, or is one of those are those the same as decarboxylation that you do for edibles to get the Delta-9-THC? Is there something different with those two methods with those two words?

Emma: So hydroxylation and oxidation of THC are not the same as decarboxylation. So decarboxylation, just to review, is removing a carboxyl group which is a carbon and oxygen, an oxygen and a hydrogen, and that carboxyl group makes THC an acid and so in its raw form THC exists as THC-A or THC acid because it has that carboxyl group when you heat it at a certain temperature over time you remove that carboxyl group from that compound and then you get Delta-9-THC. When we consume Delta-9-THC whether through its inhalation or oral ingestion, it does undergo a hydroxylation reaction and most of us are very aware of this hydroxylation reaction, only when looking at the consumption method of oral ingestion and talked about it a lot and there is a lot of literature on like, blogs on the internet per se that when you do consume an edible the Delta-9-THC undergoes a process in your liver where it turns into 11-Hydroxy-THC. 11-Hydroxy-THC being the analyte that is much smaller than delta-9, so it can more easily penetrate into the brain through the blood brain barrier. And it also has a higher binding efficiency for your CB-1 receptors, which translates to a much greater psychotropic activity and so that is why edibles have such a psychotropically intense experience, why they deliver an experience that is rather intense for a longer period of time than inhalation.

But what we don't talk about is that Delta-9 also undergoes that hydroxylation reaction and turns into 11-Hydroxy-THC when you inhale; so when you inhale whether you are smoking or inhaling with a vaporization device, you are inhaling the Delta-9-THC as heat will decarboxylate the THC-A in that moment, but then when you inhale 90% of the THC in in your blood is circulated in plasma and the rest in in blood cells. So when we think about bioavailability and when we take these different markers of THC, we're measuring it in the plasma just to let everybody know. And what we see after inhalation is that Delta-9-THC is detectable in plasma in seconds, so within seconds after inhalation you'll see Delta-9-THC in plasma but really peak concentration of the Delta-9-THC in the plasma is it is attained within three to 10 minutes so it's rather quick and max Delta-9-THC plasma concentration is observed at approximately eight minutes after smoking 11-Hydroxy-THC concentration peaks at around 15 minutes after smoking.

So again, Delta-9 is undergoing this hydroxylation reaction even when you inhale even as it's circulating through the body in the plasma, and then it undergoes another reaction, an oxidation reaction that turns THC into 11-nor-9-carboxy-THC. And this 11-nor-9-carboxy THC is quote unquote inactive - it does not have any psychotropic effects, and it's actually the analyte of THC that drug tests test for, so if you've ever take in a urine analysis? The analysis is testing for that specific analyte of THC, because it is the inactive form. It's the form that kind of hangs around in your body for a relatively long time after consuming. And what we see with smoking or inhaling is that the 11-nor-9-carboxy-THC peaks at around 81 minutes. So that means that for most people, after an hour and 20 minutes after smoking or inhalation, you'll pretty much level out into a normal kind of state, you won't have much psychotropic activity after that. And of course, this does depend on the depth of inhalation, the concentration of THC, all of that kind of stuff, how much you're smoking, how consistently you're smoking, etc. As far as bioavailability through inhalation, THC bioavailability for heavy users is around 23 to 27%, where it drops significantly to around 10 to 14% for occasional users, and a lot of that THC is also lost through pyrolysis. So through that combustion reaction, a good amount of THC is lost as well. So that's what smoking and inhalation now when we go to oral ingestion, it does something a little bit different. So like I said, when I started talking about this, most of us know that when we consume it, Delta-9-THC undergoes a process through the liver where it turns into this 11-Hydroxy-THC. And that is still very true. Maximum Delta-9-THC plasma concentration after oral ingestion, you typically see that within one to two hours, which is that kind of latent active time and that's because the THC does have to go through the liver. So especially if it is suspended in fat, which most cannabinoids are most edibles employ a fat infusion, then your compounds will have to undergo first pass metabolism through the liver. And this is where the liver wastes out a lot of the compounds, a lot of the THC and therefore, liver metabolism just reduced that bioavailability marker by about four to 12%. And so if you're a heavy user, and you get 23 to 27% THC bioavailability through inhalation, well that's going to be reduced by around four to 12% if you're going to be ingesting it orally, but it kind of makes up for that because a higher concentration of that delta-9-THC is turned into 11-hydroxy-THC through the liver. So a much higher concentration of that 11-Hydroxy-THC is produced after ingestion as compared to inhalation. So we're still having this hydroxylation reaction in both consumption methods. However, you're just getting more of that 11-Hydroxy-THC through ingestion, and that's again why the experience is more intense for edibles. Following the assimilation via the blood, meaning following Delta-9's and 11-Hydroxy-THC's penetration into the bloodstream and carried around through plasma all over the body, then the THC rapidly penetrates into fat tissues, and highly vascular, vascularized tissues as well, including brain and muscle. And this then results in a rapid decrease in the plasma concentration because those compounds are really penetrating into the fatty tissues and into the brain. And then this tissue distribution, so THC being in these tissues is then followed by a slow redistribution of it from the deep fat deposits back into the bloodstream. So with ingestion, that is a, that's also something that happens more frequently than inhalation where THC is really penetrating into these tissues sticking around in the tissues for a while. And then after a certain period of time dependent on everybody's unique chemistry and, and metabolic rate, then the THC will slowly go back into the bloodstream and into the plasma once again. But that form of THC will be largely the 11-nor-9-carboxy analyte that again, is rather inactive and that can stick around in your body for quite some time, leading people to have positive drug test sometimes, even after they've abstain from cannabis for a while.

Wayne: Yeah, that's interesting. I didn't know about the 11-nor-9-carboxy being the one they test for and also another conversion that happens as the inert and inactive version. How does, so I've you know, we've talked before about eating the edible and the 11-Hydroxy conversion that happens and how that seems to be more potent or more psychoactive. And so that happens through the metabolism in the liver. How does it happen when smoking? How do you get 11-Hydroxy while smoking when there's no, that metabolism process isn't happening in the liver - is there a different way it converts or something else going on?

Emma: So our body is still metabolizing it, but just in a different way. And so with liver metabolism, that's where you get the much higher concentration of the 11-Hydroxy. But the analyte of Delta-9-THC is still being metabolized as it's circulating in the plasma, because it is a foreign compound. And so our body is still trying to like change it and figure out what it is and get it to a point where we're wasting it out ultimately. But and so it does undergo hydroxylation reaction while circulating through the plasma, yeah.

Wayne: Okay, fascinating. Do we have any idea of what percentage 11-Hydroxy is created when eating versus what percentage is created when smoking?

Emma: Hmm, we don't have a good kind of like universal conversion percentage. From what I've seen, just the research does point to a much higher concentration of 11-Hydroxy produced and again, it will be dependent on each person's unique chemistry and metabolic rate and physiology and etc, etc. to really determine that rate of conversion for each person.

Wayne: Yeah, yeah, I find the bioavailability interesting when it's so you know, higher for smoking and lower for an edible or eating, but you see more of that 11-Hydroxy created, maybe making up for that decrease bioavailability. Do you know or can you kind of explain the listeners, and if we know anything around this, what it is about 11-Hydroxy being more effective - if that's the right word - compared to Delta-9 and how it interacts with our body and the differences there?

Emma: Definitely. So to start the 11-Hydroxy-THC analyte is much smaller than the Delta-9-THC analyte. And so when we think about those compounds crossing our blood brain barrier and coming up against this channel of resistance that is based on how big the compounds are, the bigger the size, the greater the resistance those compounds will meet when trying to enter into the brain, well then 11-Hydroxy being the smaller compound will have a much easier time crossing that blood brain barrier and getting into the brain. So already, you're just going to have a more efficient process of that particular analyte, the 11-Hydroxy, just penetrating into the brain. And then when we talk about phytocannabinoids in our Endocannabinoid Receptor System, the phytocannabinoids actually have very low affinity for our Endocannabinoid receptors. And so THC while it does bind to the CB-1 receptor, Delta-9-THC in particular, it doesn't really love to bind to the CB-1 receptor, it's not something where it's like, it has such high affinity for it. Whereas 11-Hydroxy-THC comparatively to Delta-9 has a much higher affinity for these receptors, meaning that it will go and bind to the much quicker than Delta-9 would, and so even if you have a smaller amount of 11-Hydroxy-THC compared to Delta-9, it may still create a more intense psychotropic experience because that smaller amount will more effectively engage with those CB-1 receptors to initiate the signaling pathways to cause that cerebral high.

Wayne: Yeah, we've always kind of known that with edibles, that they can create a stronger high, but almost a different high, I wonder if, you know the, it's more - has more affinity to bind, which means it could be more either bioavailability or more potent. But would the 11-Hydroxy versus Delta-9 bind differently? Or is that high from 11-Hydroxy different in some way compared to Delta-9? Or does it just bind more, so it has more of an effect that way?

Emma: It does bind more, which means that it just it likes to bind to the receptors more. I'm not sure if it if there has been research done that really measures the difference in effect. I mean, it's also hard because these types of reports are so subjective to the actual consumer. And so when you're looking to measure experience, you need that aggregate anecdotal data that does require those subjective consumer reports. You can also and should also run tests that require kind of a level of scientific rigor where you are looking at this one particular analyte and measuring its responses but still, to really translate that into experience you need the combination of the aggregate anecdotal, which again can get subjective and is so specific to everybody because everybody's Endocannabinoid Receptor System is so unique.

Wayne: Yeah, yeah. When it comes to smoking and vaping are those both going to be similar in how the THC is converted to the Delta-9 and then how it gets changed to 11-Hydroxy in the plasma or in the system when you're smoking the flower versus vaping concentrated extract?

Emma: Yes, so that particular hydroxylation and oxidation reaction will be very similar because it is, just looking at it through the pathway, the consumption method of inhalation, which is common to both smoking and vaporizing. I think that with smoking, you may lose some more THC than you would with vaporization, especially vaporization of flower if it's contained in a kind of convection heating model. You'll want to make sure that your temperature is high enough where you are decarboxylating those acidic compounds as much as possible, you are activating them. However, if the hydroxylation and oxidation pathways will be the same, the concentrations just may differ, where you just may get more THC from a vaporization device, whether it be flower or oil because of course the oil will have a higher concentration of THC to start. So you will get a higher concentration of THC then delivered to your bloodstream, vaporization of flower because the flower is contained in convection heating, you won't lose so many of those compounds to pyrolysis and then the combustion reaction, of course, you may lose a lot more of those volatile compounds, including some THC, just because of that combustion reaction.

Wayne: Right, ok. Is - knowing that the 11-Hydroxy is created when smoking, is that something new that was discovered recently? Or has this been known for a while? And then I want to ask another question on that - Is there anything a consumer can do while smoking that may help increase how much is converted to 11-Hydroxy; eat something, smoke something else with it, anything like that?

Emma: So the study that I am citing in particular around these Hydroxylation oxidation reactions is from 2012. So we've known this for a little while, and really where I've seen this information come to the best use is when kind of talking people down from a really intense experience, too intense of a psychotropic experience. Maybe they smoke too much THC or they consumed too much THC through oral ingestion. I recently had it be the case where my little sister who, she is in New York, she like hit her friend's dab pen and texted me and she was like, "Oh, my God Emma I'm so high, please help me. Like I, I need help. I don't know what to do." And so I started talking to her. And what I found really helps when people are having this experience is to kind of give them an idea of what's happening in their body. So we're really like, ground them in their body and say, “okay, your heart rate is super high. Your heart's beating so fast, because THC is opening up all those blood vessels, getting the blood rushing.” “You are having this anxious, paranoid experience because THC is binding to your receptors in your brain and making you feel this way.” And another thing that I told her was that well, how long has it been since you last hit it? And she was like, probably around like 15 minutes or something. And I was like, “Okay, well, your 11-Hydroxy-THC, the form of THC that makes you super high, is peaking right now. And so you just need to get past this hump, and then you will feel yourself calm down”. And by just giving her that knowledge, she was able to put herself more in control of her experience, and have that relieved moment where it was like, "Okay, okay, I'm at the highest that I'll be right now, and we will taper down off of that." So that's really where I've seen this information be that come into play when, when talking consumers through a really uncomfortable experience. I don't know if there is anything that one can do to increase the concentration of 11-Hydroxy that is produced. I mean, I know that just like any metabolic reaction, it is catalyzed by an enzyme. And so I'm not sure what that is for the Delta-9 to 11-Hydroxy conversion, what, what that reaction needs in order to have it go, but if you can isolate whatever it is that that reaction is dependent upon, whether it be an enzyme or heat or whatever it may be, and then administer that, co-administer that with Delta-9-THC, then theoretically, you could increase the concentration of 11-Hydroxy-THC.

Wayne: Yeah, I'm so fascinated by both of those, as we learn more about other minor cannabinoids and how those can influence the effects, to learn more about Delta-9 verses 11-Hydroxy, and will it almost be viewed as two different things to look at, or if it is just that 11-Hydroxy binds better, or if it's making this high experience different in some kind of way. Because it does seem to feel, to be some difference between an edible experience versus smoking. Some of the times but again, there's different strains and different expected, both can be different. Is there anything on that, for the edibles that does - when you consume an edible, does 100% of the Delta-9 get converted to 11-Hydroxy? Or is there both of those existing in the edible experience and would there be any value in trying to have more Delta-9 than the 11-Hydroxy in an edible?

Emma: So both of them do exist after liver metabolism. And so no, not all of the Delta-9 gets converted into 11-Hydroxy, a much higher concentration does but you still will have some Delta-9 that will penetrate through the digestive tract into the bloodstream and then into the tissues as well. The therapeutic value of increasing the concentration of Delta-9-THC as opposed to 11-Hydroxy-THC through oral ingestion, I think would be for the consumers who do not want such an intense psychotropic experience but could benefit from cannabinoid therapy and medicine but they don't want to inhale any hot smoke or vapor and they also want like a deep penetration into the bloodstream and the circulating tissues, and so oral ingestion then is favorable for that case. However, it does give quite a psychotropic reaction and so employing some method where you're either bypassing liver metabolism entirely, which would be nano-encapsulation or nano-emulsification of delta-9-THC to increase the amount of delta-9 that penetrates into the bloodstream as compared to 11-Hydroxy is a way to go, or doing something else creating some other kind of product formulation that will allow the compounds to go through the liver. However, you won't see such a high rate of conversion into 11-Hydroxy-THC. I think that that's absolutely coming. I think that with cannabis, it's really exciting, as we're seeing more research come out, new product formulations are coming out on the scene. Really looking at the combinations of different cannabinoids and terpenes to optimize the therapeutic action and the experience for many different consumers, and one such consumer base does want the ability to orally ingest THC without feeling much psychotropic activity and they want the active form of THC they want that Delta-9, they don't want just THC-A, and so finding innovative ways to do that, I think is, is an exciting part of this industry.

Wayne: Yeah, yeah. Two different customer groups or, or needs there. What about sublingually, when we absorb under the tongue or something like that? Is it basically all, mostly all Delta-9 then that you would be getting in the body and maybe a little bit of 11-Hydroxy similar to smoking? Versus when you consume sublingually under the tongue and through the mucus glands?

Emma: Yes. So we think that through sublingual consumption that you will see a similar conversion rate from Delta-9 into 11-Hydroxy into 11-nor-9-carboxy as you would through inhalation, as you would through smoking. And that's why you can have in a more immediate onset of effects, but it will not be as intense from a high standpoint as an oral ingestion.

Wayne: Got it, Okay, that's interesting. And one other thing on this, you mentioned the bioavailability when smoking 23 to 27% for heavy users, but almost half of that 10 to 14% for normal users. Why is there such a difference in the bioavailability for those two different user groups?

Emma: I think that one, with heavy users, those people, that base, understands at this point how to consume THC and they'll consume a lot more of it, meaning they'll hold it really deep in their lungs and hold it in there before fully blowing out, that they will generally consume varieties with higher concentrations of THC. So they just have more experience actually knowing how to consume the plant. And, and really I think that the main factor there is length and depth of inhalation, so how much they're inhaling and how they're holding it in. But there's also something to be said that with heavy users, they are their bodies are primed for metabolism of these compounds, of these phytocannabinoids, because they can consume them all the time. And so I think that the body is just more prepared to uptake these compounds. And it's a phenomenon that we see with people who are just starting to smoke cannabis, that they may not feel anything for the first few times, right? And I, I believe that's because the body needs to be primed. The endocannabinoid system needs to kind of be woken up to these compounds, in order to most effectively engage with them. Whereas with heavy users, well, the body is definitely woken up to these phytocannabinoids and they understand what to do with them at this point. And so you do see a higher rate of uptake by the body.

Wayne: Got it. Okay. Interesting. I want to switch over to some questions we got from a listener and they're mostly focused around edibles. And I think these will be interesting. We talked a little bit about the THC stuff we just talked about, and then maybe how terpenes or even CBD comes into these. The first question she asked was, can edibles really produce an uplifting or sedate of effect once THC has been converted to the 11-Hydroxy-THC? And she said her experience she says, I think they all act like hybrids to her. Unless a person takes too much then she either feels paranoid or sleepy. So she's kind of says that she thinks all edibles have a very similar experience more like a hybrid. But is there anything around that or studies that we know of edibles can be more uplifting effects versus relaxing or sedating?

Emma: Sure, So, this is - one, it's important to note that since we just had this conversation that 11-Hydroxy-THC, you will have that experience with that analyte whether you are smoking, inhaling, vaporizing, or ingesting, ingesting, so it's not the 11-Hydroxy that will deliver a kind of consistent experience for all edibles, because it's not exclusive to edibles, which we now know. What we're then talking about are really the bioavailability of terpenes, because terpenes are the compounds that are thought to be responsible for the more nuanced effects that are produced by different cannabis varieties. And so with edibles and oral ingestion, we can say, “Well, okay, how many terpenes are actually making it into the blood plasma to cause a certain effect?” And there have been studies done on this where, through the more like scientific rigor, individual terpenes were tested for blood plasma levels after consumption, just like THC or CBD, would to measure bioavailability. And what they found was that there were not many terpenes that made it through into the plasma. There were some like larger, heavier terpenes that did have more resilience and did make it through. However, a lot of them did not. This is not to say, though, that the terpenes are not having any action on receptors or factors before they enter into the blood plasma, especially in the digestive tract. So during digestion, and during liver metabolism, there are a lot of enzymes that play, there are a lot of physiological factors that go into that metabolic process of digestion. And terpenes may be having some type of effect on those factors, before they're even able to make it into the bloodstream. It's also important to note that terpenes do show up in sweat. So they're going somewhere, they're going somewhere, and then they're coming out that way. And so I don't think that at this point, we have enough conclusive scientific evidence to write off the difference in experience, the difference in edible experience. Also, it gets, again, tricky when you look to measure this kind of experience in humans, we have to do at this point, anecdotal self reporting, which is subjective, because we cannot do human clinical trials. And so when we do this kind of subjective reporting, you will see many people who feel like they are having an uplifting experience or a relaxing experience, it's really hard to measure if that's a placebo, or not. At this point. I can say from my personal experience, I definitely had edibles where I have felt way more uplifted versus way more relaxed and sedated. I don't think that it was a placebo effect for me, because I also consistently would have those experiences with this particular company that did do strain-specific edibles. However, that is just my personal experience. And that does not hold up in the realm of science, right? We can't extrapolate that and say, "Well, now all strain-specific edibles, yes, they will absolutely give different experiences." It's definitely worth researching further, because there is a lot to be elucidated around the way in which these compounds interact with each other before they do even get into the bloodstream, particularly with oral ingestion. And so at this point, like I said, we don't have enough scientific evidence to say, yes, these edibles, these strain-specific edibles, do actually cause a different set of effects based on the compounds because the terpenes do XY and Z. But we also don't have enough conclusive scientific evidence to say no, that edibles universally give the same experience, and they don't actually have any nuance of effects. And that's just where we're at right now.

Wayne: Yeah, and I like how you said it nuanced effects, not like black and white effects, like a sleeping pill, or, you know, cocaine as a bad example, to have that kind of extreme uplifting versus sedating. It's not like that. It's very nuanced, and has a lot to do with your current state. where you're at, if you're tired already, are you already feeling kind of up and positive? There's probably an interesting, yeah, a nice way to look at it.

Emma: Exactly. And it is hard when we talk about cannabis in this kind of dichotomy, because I don't think that relaxing and uplifting really do those experiences justice in the sense of like, being able to describe them; of course, you will have your extremes where it's like, "Whoa, I like really need to like move or go on a hike or clean the house". And then you'll also have the opposite extreme where it's like "I can, I cannot lift myself up off the couch". But there's a lot in the middle there that is just more of a shift in perception. And the way that I described in myself as almost like a zooming out or zooming in - where I either get like really focused on something or I have more like a zoom out perspective, where I can like connect more the dots in my brain for whatever it is I'm thinking about. And then of course, you have like, chatty, or silly, or quiet, or self aware. I mean, there's so many ways that we can describe these experiences, they're so unique to the person like you mentioned, they're so dependent on the situational awareness on your mental, emotional, physical health states while you consume, where you consume, who you're with. That, it's a, it's really hard to measure and then statistically analyze and extrapolate to the entire population.

Wayne: Yeah, yeah. I like that too, the zoomed in versus zoomed out. I have noticed that with different products where I can get hyper focused on something very specific and do that for a few hours versus have this experience of just big picture abstract thinking but have a problem or trouble trying to like be very focused with the attention. So I have noticed that, that's I've never heard anyone describe it that way, though. I like that, what about sublingual versus ingesting the edible around terpenes and the effects? Is there more availability sublingually potentially?

Emma: I can't say this for certain as I have not come across a scientific study that looks at the bioavailability of terpenes sublingually versus oral ingestion, specifically in the context of cannabis. But I would theorize or hypothesize that yes, terpenes would be able to penetrate into the bloodstream more effectively, especially because terpenes again, are quite small compounds and they really easily penetrate through our mucous membranes as well as the blood brain barrier. And so I, I would think that again, the bioavailability of those compounds is more similar to an inhalation especially vaporizing flower at low temperature inhalation because when we talk about combustion, or dabbing or anything like that, I mean that like super high heat will definitely destroy a lot of terpenes. And so by consuming terpenes sublingually, you're not applying any heat to them and therefore, they will be able to or should be able to, there should be a higher concentration of them when they are crossing the mucous membrane there. So I would think that again, it's only hypothesis is I haven't seen any scientific research to corroborate this, but I would think that terpenes would be more bioavailable through the sublingual method as compared to oral ingestion.

Wayne: Okay. And then she also, she followed up and asked from the consumers perspective, what should a consumer ask to get a product that is, you know, quotations uplifting versus sedating. Besides just reading an "S" or an "I" on the label, I think she, she probably meant sativa or indica so maybe we can briefly hit on that. And then she said, should they be asking their budtenders about the extraction method used to infuse an edible and/or if the terpenes are added back in?

Emma: Hmm, yes. So, I'll answer the first question first. So when a consumer is looking to really get a targeted experience, whether it be more uplifting or more sedating, they need to ask about terpenes. Terpenes are the compounds that we think, at this point, are responsible for delivering those unique set of nuanced effects and experiences. And so if you are seeking something that is more euphoric, joyful, that will give a more social silly effect then look to, or ask for, the terpenes that are more citrus and pine in aroma, and you don't even need to remember their names their names for reference are Limonene and Pinene, but you just need to remember their smell and ask the budtender for that smell. So citrus and pine, do you have anything that smells like citrus or pine. If the shop has terpene results, awesome. Ask them for Limonene or Pinene. Or even if you don't remember those names, you can still ask them for citrus or pine and they should be able to point to you to those terpenes with actual results to back it up which is exciting. On the opposite end of the on the spectrum if you want somebody to help with sleep then asked for varieties that smell more like hay, or spicy pepper or even Linalool which is the terpene found in lavender. It'll give a more like floral but still earthy aroma. So anything that smells kind of like that like sweet grape, tropical fruit, earthy dirty aroma is something that you want when you are trying to select for a more sedating experience. With edibles, if you want something that is more uplifting or relaxing or is designed for a more targeted experience, then ask one, strain specificity. So many edible companies will do some form of strain specificity. So ask your budtender if they carry any edibles that do that. Otherwise ask for any edibles that do really try to target for a certain experience. A lot of times those edibles will share that information on their package. I know Wayne that you do that with Periodic edibles, which is great. And so the consumer can really easily kind of look at the package and be able to tell "Okay, this edible company is trying to market to a certain experience as compared to this other one that isn't" and then really, the overarching theme with cannabis and cannabis products that I encourage everybody to adopt integrate is experiment with yourself - just try it out, take a tiny little bit, and make sure that you're in a like a space with people that you trust and that you're comfortable in, you don't have anywhere to be necessarily and you could just have that experience with yourself and see how it makes you feel. If it doesn't make you feel the way that you want it to, then you never have to consume it again. Or you could do a dose increase or decrease until you find the optimal dose that does give you that targeted experience. And then take that information back to your budtender, especially if you have a budtender that you trust, go back to them and share with them your experience - even if it was out of line of what you wanted or what they predicted for you, still share that with them because that will help them gather that much more information about you so that they can make a better prediction for you moving forward, better recommendation for you moving forward.

Wayne: That makes sense. How much do you think minor cannabinoids will, you know you said terpenes really can be responsible for these nuanced effects. Do you think as we discover and more strains have other minor cannabinoids in them, those will also be able to have these different effects, nuanced effects like the terpenes do?

Emma: Definitely. Oh definitely, especially in combination with other terpenes and major cannabinoids. So for example, THCV and Limonene and CBD give really like potent anorexic effects, meaning that they really suppress the appetite, more so than any one of them could do on its own. Right. And then there's also Linalool and THCA and CBD which really increases the anti-convulsant potential of a variety, and so it helps to relax the body, it helps to give a much deeper muscle relaxing effect. So those kind of synergisms will absolutely start to come into play more and more. And again, I think the future of cannabis product formulation is in this kind of designing of and optimizing of the Ensemble Effect is really elevating concentrations of THCV, CBG, CBC with other terpenes to produce a really targeted therapeutic experience.

Wayne: Yeah, yeah. Exciting. Yeah, so many options there. And then the minor cannabinoids, do you think they will have a bigger result on effects over the terpenes potentially, or certain ones might?

Emma: I think they absolutely could. Yeah, I think that my prediction is that the next like superstar cannabinoid, so like CBD I consider the superstar right now, I think that CBG is going to really come into play as the like next superstar cannabinoid for all of its amazing therapeutic potential, specifically, in regards to its ability to manage digestive disorders and its ability to have a really potent anti-anxiety, anti-depressant effect. I think that we're going to see a lot more of that coming on to the scene. And because these cannabinoids can and do interact with our Endocannabinoid Receptor System and all so again, have these synergistic effects with other major cannabinoids as well as terpenes, I think that an elevated concentration of knows could really influence the overall experience.

Wayne: Yeah, yeah. And then I want to now switch over to how either, this could be looked at either way, how a budtender can communicate this information to customers, especially new customers that are just coming into cannabis or just learning about the science. And I guess it could be thought of as, how can customers look at products when they want to purchase something? And that was something else she asked in her question is, you know, we almost just had a 30 minute conversation on THC alone and the different conversions and things that happen. Obviously, every budtender and customer can't have that long of a conversation. How do you recommend budtenders have the conversation around science and cannabis with consumers?

Emma: Great question. I teach workshops that I've been developing for a while now on this topic, because it's so important, right? We learn all of this information on the fundamentals of cannabis science, it's really exciting, we get to nerd out on it a lot. Most of, most people who are in the industry love it, because we want to learn more. But then we have these, these retail transactions with customers who do want reliable scientific information specifically around the experience of the product that they will purchase. And yet it has to be done in like 10 minutes or less. And it takes a level of finesse to get there. The way that I have done it myself, and the way that I teach, is to really ask specific questions. So that one, you can assess where your customer's at - do they want an educational experience? Do they want to stay in there with you for half an hour? Or do they want something quick and easy? Like a pre roll and just like get out and go? Or do they want to fall somewhere in the middle where they're interested in learning more but they don't necessarily want to be there for 30 minutes. And so the one of the first questions that I'd ask to a customer is - what kind of experience are you looking for? Do you want something that is going to be more uplifting? Do you want something that's going to be more sedating? To just try to assess where your customers at with that, then they'll give you their answer. And then you make your product recommendation based on the cannabinoid and terpene content of the specific product. And of course, you'll make that product recommendation also around what they actually want to consume. And so that's another question that you'll need to ask well, do you want to smoke flower? Are you interested in edibles? What product area are you interested in? Because that will also determine how much information you share and what kind of information you share. But the main, the main point is to make sure that you are basing your prediction for their experience on the cannabinoid and if you have available the terpene potency and ratio of this specific product.

Now I also recommend frequently checking in with your customer. So if you pull out let's say they're interested in smoking flower, you pull out a cannabis variety that has some more Limonene and Pinene because they wanted something more giggly, social chatty, and you're talking to them about the cannabinoid concentration and the terpene concentration. Well, they may not know what cannabinoids and terpenes are, and so before I would even dive into that kind of information, I would ask my customer, “Are you familiar with cannabinoids and terpenes?” and you give them the opportunity to say yes or no. If they say no, then ask them well would you like to learn more about them? So you're putting their experience in their hands. They are in control of their experience. If they don't know about cannabinoids and terpenes but also they don't care to know, then they'll say “No, no, I don't know about cannabinoids and terpenes." No, I don't really care to learn, I trust you.” Or if they say “yes, I would like to learn more”, keep it brief. Cannabinoids are the main class of compounds found in cannabis. They will really drive the experience. Your major cannabinoids are THC and CBD in this particular variety, you're going to have 24% THC, 1% CBD that will give a generally intense psychotropic reaction so you're going to want to make sure that you're dosing appropriately for yourself, do you know your dose? If they don't know their dose, then ask them again, well would you like to learn about strategies for microdosing? Really, again, keeping them in control of their experience is the number one goal - making sure that they have exactly the experience that they want. So frequently checking in with them, asking them questions. Now, when it comes to terpenes, terpenes are the aromatic compounds found all plants, they give plants their smell, they're also abundantly found in cannabis. And in cannabis, they're thought to really be responsible for the different nuances of experience that different varieties can provide, for example, Limonene is a terpene that's found in this particular variety that you're interested in. It's also found in the rinds of citrus fruits, and in many, many household cleaning products. So think when you smell a citrus fruit in the morning, or when you're like spending a Sunday afternoon deep cleaning your house, you generally feel a sense of uplifting energy, it feels exhilarating, it feels euphoric, it may even feel joyful. That's Limonene doing its job, it'll do the same thing when you smoke it in cannabis. So just keeping it really brief, really accessible, and constantly checking in with your customer to make sure that they're on the same page you; that you haven't just rattled off a ton of information to them without their permission, and now they're lost and overwhelmed and don't know what's up and what's down. That's the most important thing is keeping your definitions really short, really accessible, using analogies to describe different compounds and effects - I find that to be particularly helpful when talking about terpenes with people. So again, you can build a bridge to something that they're comfortable with, that they can relate to. And you're not just throwing out these words - Limonene, Pinene, Linalool, beta-Caryophyllene - that they've never heard before, and yet they've interacted with almost on a daily basis. And checking in with them constantly even after you may have gone like a, let's say, you explain that terpene spiel that I just said, you can even ask afterwards, “does that make sense to you? Like, do you - does that make sense?” That way, they can have the opportunity to be like “No, actually, I'm lost.” You can backtrack and help them. Or they have the opportunity again to say “Yes, that makes sense.” Cool. And so that's really what it's about. It's finding that balance of being able to deliver this information that is important for them to know and understand in a really easy, quick, digestible manner, and then also making sure that they are getting the experience that they want, by asking frequent questions, and really making sure that they're in control of their own experience every step of the way.

Wayne: Yeah, I love that permission checking piece at each kind of point, because I think that's where I've struggled, I think budtenders do is they get on the, into the science, and then they start, you know, on a rant basically, and you can get too deep where then the customer feels overwhelmed. But checking along that entire conversation at every step forward makes a lot of sense. And then I think that what you said making the customer feel in control of that conversation and influencing it in the direction they want, is really going to create a customer that has a great experience at your store and most likely is going to want to come back to the store.

Emma: Exactly, I mean, all that we talked about today, right like the Delta-9 into 11-Hydroxy into 11-nor-9-carboxy and the bioavailability points and metabolic conversions - like your customer, your novice customer does not need to know that. You do not need to share that with them unless they are very interested and want to learn more and make it clear that they want to learn more. But really this information is for budtenders to be able to make better predictions to customers regarding experience, you do not need to fully explain to them and flesh out every single scientific point and learning opportunity that you've had that have led you to that prediction. You just need to give them the basics and, and even then make sure they want it. I mean, there may be people who just are like, I want to come in, I want to grab my pre roll, what do you have that has, that will give me like the most sedating effect in your pre rolls? And you tell them uh, well I have this Grape Kush, it has a high level of Myrcene. Here you go. And that may be that - that's all they may want, and then they'll purchase it and get out. You never want to knowledge shame. You never want to inundate people with so much information that they are just completely overwhelmed. Again, they have to be in control of their own experience.

Wayne: If a customer were to come in and say, and I'm guessing a lot of budtenders have this conversation still, you know, "I want your strongest Sativa”, or “I want your strongest Indica." How do you guide that conversation?

Emma: So this brings up more of that knowledge shaming that I mentioned. So we never, ever want to knowledge shame. I know that you all know behind the counter, if somebody comes in and they're like, I want your strongest Sativa that you have, you pretty much know what they mean. And so there is no need for you to say, "Well, no, no, no, Sativa and Indica actually do not correlate to consistent experience. So you're wrong. Let me tell you why you're wrong." And then like go on the full history of like Linnaeus and Lamarck and yada yada yada? Again, you do not need to share that with them. That information is for you to make a better prediction of experience for your customer so that you don't rely on the Indica/Sativa distinction to make a prediction for a customer because it, it has a high likelihood of being wrong.

Wayne: Yeah, yeah.

Emma: But, you still don't want to reinforce the concept that Sativa equals super uplifting all the time. And so how I've, again and how I teach on how to manage this type of interaction is by - Okay, a customer comes in and says “I want your heaviest Indica” well, or “heaviest Sativa”. Then you can say, "Well, what kind of, what kind of particular experience are you looking for? Do you want to be like really focused and get a lot of work done? Do you want to go on a hike? Do you want to go out dancing, like Sativa is very general umbrella term, that means uplifting, but it has many, again, nuances underneath that umbrella. So really ask the question to your customer to elucidate more specifics about what they do want to actually experience. And then, and then we'll move into more language around their experience. They'll say, "Well, I want to go out dancing with friends." And they may even reiterate, so I need your heaviest Sativa, your like, the thing that's going to make me most energized. And again, you can say okay, cool, so you know more about their experience now. And you can pull out a variety of cultivar that has maybe let's say some Terpinolene, has some Terpinolene, has some THC, let them smell it and say, "Okay, well, I'm pulling out this Super Silver Haze for you, because it has 23% THC. And it has this compound in it called Terpinolene that, especially when you consume it with THC, it gives a really, really kind of like speedy energy, so perfect for dancing for concerts.” Ask them if they've ever had Super Silver Haze before. If they say no, then make sure to advise on dosing strategies because Terpinolene can get a little wonky if it is consumed in high concentrations, and then have them go on their way if they choose to purchase it. At no point did you ever say Sativa - you never needed to include the language of Sativa. In fact, you had a little educational moment where you even mentioned the terpene, Terpinolene, that was in a variety, which was why you were recommended it to that customer. And the idea here is to have that person go to her concert, smoke that weed and get exactly the experience that she wanted. So then she comes back to you, and the next time maybe she doesn't say, “Oh I want your heaviest Sativa” but she says “oh, I want that thing that you gave me that had that other thing in it, Terpino-something.” And there you have just planted the little seed of removing the idea of being only stuck in the Indica/Sativa dichotomy and instead expanding that into cannabinoid and terpene conversation - into a conversation that is rooted more in experience, which is the goal. If you were to say, right off the bat when that customer came in, "No, no, no, Sativa is wrong, you're wrong." That customer would have shut down, people hate being told that they're wrong. And it's not, it's not a way to open up a dialogue for, for this kind of ongoing education. It's not, it will just shut people down. And so instead, you need to work with your customers, you need to work with the language that you're giving, that they're giving you and help to gently guide them out of that language because they just don't know any better. That's what they've been told is the vernacular to describe experience in the cannabis community. And it still is largely, but as we know, there's so much more than that. And again, your job as a budtender, is to make sure that you're not using that distinction to predict experience. And just by doing that job, you will help to really convert a lot of the people who still solely rely on Indica/Sativa because they don't know any better.

Wayne: Yeah, yeah. I love that perspective to keep that conversation dialogue open. And I think you're exactly right. As soon as you tell someone they're wrong and they have any of that kind of feeling, defensiveness turns on immediately, and they probably don't have full trust with you yet. So they get a little, there's confusion there and the conversation stops. If we were to take that even a little further and the customer were to come back and say I really liked that terpene you told me about, Terpinolene. So I'd like another Sativa strain that has Terpinolene in it, because it - what if they make the connection that Sativa equals Terpinolene or certain terpenes - do you know what I mean?

Emma: Mm-hmm. I think that's fine. I think that's a first step in the road of really beginning to understand the complexity of the cannabis matrix. And so if they want to correlate that, okay, Sativa is - I want another Sativa with that terpene in it. Well, at least they are correlating an uplifting experience to that terpene because that's what Sativa means to them. And it does not mean the cannabis species that was first identified by Carl Linnaeus and that only is associated with a certain plant morphology, right? Sativa to them means an uplifting experience. They're just using that word in place of uplifting. And again, we don't need to change that for them. That's their vernacular, that's cool, they can use that. They are looking to budtenders to get the experience that they're trying to communicate that they want. They're just using language that we know is not exactly right. It's not language that we could ever use as industry professionals, as budtenders to then predict a consistent solid experience for the consumer. And that's where it is most important for budtenders to have this understanding. that Sativa and Indica does not correlate to consistent experience so that they can make better predictions for customers, even if those customers are still using those terms to describe experience, if that makes sense.

Wayne: Yeah, that's where the kind of mastery comes from, for the budtenders to learn this at this deep level, but then able to - which I think you do so well - is able to simplify it to present it to the consumer in that way where you're presenting the new information and asking those questions along the way, I think that's great.

Emma: Yeah, exactly.

Wayne: Yeah, thank you for that. I think that will help a lot of budtenders.

Emma: Good!

Wayne: The last question I wanted to ask, I believe we covered this in the past, but I had someone else ask me about it recently. And I couldn't find it - we've done almost 12 episodes now. When eating edibles, you talked a little bit about first time consumers smoking and maybe not feeling the effects. One, because their system may not be primed for the cannabinoids. Two, maybe they're not holding the draw, or holding it in as long like a heavy normal user would. What about on the edible side? Edibles, a customer said or a budtender said a customer came in, was trying edibles and didn't have any effects on them. Is there something specific we know why edibles might just not work for certain people, like they don't experience any effects?

Emma: (It’s) dependent on metabolic rate and liver metabolism of each person's chemistry, so that definitely plays a huge factor into it. And I've also had conversations with people who at 200, 300, 400 milligrams do not feel anything when they, when they orally ingest, of THC that is. And this is a phenomenon that we see that really I think comes back to cannabis as a medicinal plant, as a botanical medicine that has such a huge dose range. So when we talk about allopathic medicine, and from the pharmaceutical model that we're also used to I mean, you take an ibuprofen, right, and most people have the certain same set of effects in a dose window between 200 and 400 milligrams of ibuprofen. Some people go a little bit above that, need to get up to 800 milligrams, some people only need 50 milligrams to experience an effect. And that's a relatively small range of dose, it may seem like a lot when you're talking about 50 to 800. But it's actually small. And that's where we get into universal standard doses. So much of what the FDA can actually approve, in terms of medicine, it has to have a universal standard dose where generally the population, 90+ percent of the population will experience the same set of effects within this 200 milligram dose range, right? When we talk about cannabis, and specifically THC, I mean, people experience therapeutic effects at 4 milligrams of THC. Other people experience therapeutic effects at 4000 milligrams of THC. And so 4 to 4000 milligrams is an incredibly large dose range. That's huge. That's a huge window. And therefore, I mean, that's why cannabis does not have the degree of consistency and predictability that pharmaceuticals could have, because of that dose range. And therefore those people who do have these experiences of, "Well, I'm eating hundreds of milligrams of THC and not experiencing anything", it may just be because they're part of the population that needs such a high dose to have any kind of set of effects. And that may be because of metabolic rate, it may be because of their ECS tone, it may be because of their liver function. I mean, it could be so many different things. And because each person has such a unique, ever-changing ECS and physiological constitution, it's really hard to identify that one thing or those few things that are responsible for that dose.

Wayne: Yeah, is that rare? That group of the population that, you know, maybe does have effects from edibles, but is in such a high range. So when they're consuming a couple hundred milligrams and not feeling it, they think they just don't work at all, is that a really small percentage that has that high of a - I don't know if you'd call it tolerance, is the right word?

Emma: Oh, I think that it's definitely smaller than the percentage of the population that does experience effects from THC, especially when orally ingested between like 5 and 20 milligrams mark. Generally, most people will experience some kind of effects between 5 and 20 milligrams of THC. And then of course, you have your more sensitive people that only need like one to two milligrams, or two and a half milligrams of THC. And then your really tolerant people that need thousands of milligrams of THC. I have not seen any kind of statistical analysis done on like really delineating the percentages of that population. There was a large scientific report that came out that we were actually just chatting about before recording, that showed that most population and it was aggregate anecdotal evidence, and so it collected over 19,000 self reported subjective consumer reports from around 3300 people. And what the research found was that most people experienced a therapeutic effect from smoking cannabis flower in the range of 10 to 19% of THC. However, it did not go into depth of inhalation, how much these people were dosing throughout the day, length of inhalation, etc. So that we still don't know, but at least it's, it's pointing to some kind of concentration range, which is a starting point. Right, all information at this point is good information in my opinion. We just need more of it to get to those specifics.

Wayne: Okay. Yeah, that makes sense. Um, well, thanks for coming on today Emma, I think we've covered a lot there and a lot of new topics as well. Is there anywhere you want to send people, maybe tell him about the website, the podcast that you and Lee from HiFi do, anything else you got going on or coming up, that you want people to check out?

Emma: Sure. So please check out my website and also if you do want to learn more about the specific ways to talk to customers around cannabis and you want to learn more about the fundamentals of cannabis science, product info, consumption methods, that I believe is necessary for the budtender population to know, then check out my workshops online eminent.teachable.com, the program is going through quite a large update and we will be migrating to a different LMS, online learning system with more engaging videos and, and different quizzes and downloadable sheets, etc. So that's coming this summer. But if you want to see what kind of information I teach on and how I teach it, then the program is live as it exists in this form right now - again, that's eminent.teachable.com. I also do do a radio show that then gets uploaded as a podcast through XRAY.FM. It's called This Is Cannabis, I host it with Lee Henderson. And we interview many people in the Oregon cannabis scene, as well as discuss some science and culture beats. So definitely check that out. And then as always, if you are new to Periodic effects, dig through these science episodes, there's so much information here that is really great again, especially if you are in this budtender community.

Wayne: Yeah, yeah, thank you. Yeah, for listeners, if they haven't - episode 50 and 51 we did with Emma. We tried to make as kind of a 101 starting point. But I feel like we've done so many episodes, and we have all this content. I'm trying to think of a way to put it on one page or condense it or tie the episodes together. But there's so much, it's difficult to put it all together. But yeah, go check out those past ones. There's a lot of valuable stuff in there from Emma. And thanks for coming on Emma. It's always a pleasure.

Emma: Of course. Thanks so much Wayne. Always love, love chatting with you.

Pe091 Why Strain Names might not Matter

Another episode focused on cannabis flower and growing. Discover why and when a strain name might not be reliable. Learn about different cultivation practices and how the plant’s development is not only affected by the cannabis genetics, but also by the epigenetics. Our guest today is Jeffrey Tambor, COO of Kind Roots.

JOB OPPORTUNITY: Kind Roots is scaling and has possible job openings, discussed in episode.

E079 Predictions on the Future of Cannabis

Will the pharmaceutical industry take over the CBD infused products market? Could CBG could be the next CBD-like cannabinoid consumers look for? Who in Oregon is leading innovation in the “craft hemp” category? All discussed with our guest Shango Los, consultant, speaker and podcast host with many years experience in cannabis, business and the science of it all.

Shango Los YouTube channel and podcast Shaping Fire and Taming THC paper link with Dr. Ethan Russo discussed in episode.

E078 Is your CBD Business in Jeopardy?

The 2018 Farm Bill has passed, Hemp CBD is now legal, but the future results may surprise you! Our guest today is David Heldreth, Founder of Panacea Plant Sciences and Content Manager for True Terpenes. We discuss negatives of the Farm Bill and how SMBs might be pushed out in preference for the pharmaceutical model. We also discuss a cannabis growth additive David has developed to increase terpene and cannabinoid potency by engaging defense mechanisms in the cannabis plant.

What can we do to prevent the Farm Bill outcome discussed in episode? The Department of Human and Health Services (HHS) is the cabinet department that oversees the FDA. Contact HHS secretary (Alex M. Azar II) who can call for the hearings and other actions needed discussed in episode. LINK for the secretary of HHS